Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) have earned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $18.3333.

A number of brokerages have issued reports on CADL. Stephens restated an “overweight” rating and set a $15.00 target price on shares of Candel Therapeutics in a research report on Monday, December 8th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Candel Therapeutics in a report on Monday, September 29th. Lifesci Capital began coverage on Candel Therapeutics in a research report on Tuesday, October 21st. They set an “outperform” rating and a $16.00 target price for the company. Zacks Research cut Candel Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, January 19th. Finally, Wall Street Zen downgraded Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th.

Candel Therapeutics Stock Performance

Shares of NASDAQ CADL opened at $6.01 on Tuesday. Candel Therapeutics has a one year low of $4.25 and a one year high of $13.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.25 and a quick ratio of 8.25. The firm has a market cap of $329.95 million, a price-to-earnings ratio of -10.54 and a beta of -0.93. The stock’s fifty day moving average price is $5.54 and its two-hundred day moving average price is $5.63.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). On average, equities analysts forecast that Candel Therapeutics will post -1.47 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CADL. Millennium Management LLC bought a new stake in Candel Therapeutics during the third quarter worth $697,000. Lido Advisors LLC acquired a new position in shares of Candel Therapeutics during the 3rd quarter worth $307,000. BNP Paribas Financial Markets lifted its position in shares of Candel Therapeutics by 128.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after buying an additional 4,439 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Candel Therapeutics by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock worth $10,236,000 after buying an additional 219,563 shares during the last quarter. Finally, Taylor Financial Group Inc. boosted its stake in Candel Therapeutics by 36.0% in the third quarter. Taylor Financial Group Inc. now owns 13,600 shares of the company’s stock valued at $69,000 after buying an additional 3,600 shares in the last quarter. 13.93% of the stock is currently owned by institutional investors and hedge funds.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.